Vγ2Vδ2 T lymphocyte-based immunotherapy

Phase 3Small molecule

SShanghai Pulmonary Hospital, Shanghai, China

Vγ2Vδ2 T lymphocyte-based immunotherapy is one of 49 small molecule programs targeting Immunotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunotherapyRecruiting

ImmunotherapyPhase 3

Recruiting

Competition

Competitive Landscape

84 competitors in Immunotherapy

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

22 2

Keytruda

Merck & Co.

Phase 3

18 3

Tecentriq

Roche

Phase 3

10 4

Taxol

Teva

Phase 3

3 5

Calquence

AstraZeneca

Phase 3

1 6

Gazyva

Roche

Phase 3

1 7

Venclexta

AbbVie

Phase 3

1 8

Paraplatin

AAvyxa

Phase 3

6 9

Yervoy

Bristol-Myers Squibb

Phase 2

8 10

Imfinzi

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Immunotherapy

NCT05493267

Clinical

Trials by Indication[1]

Immunotherapy1 trial

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT05493267·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vγ2Vδ2 T lymphocyte-based immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vγ2Vδ2 T lymphocyte-based immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vγ2Vδ2 T lymphocyte-based immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

Vγ2Vδ2 T lymphocyte-based immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News